pH-sensitive nanoliposomes for passive and CXCR-4-mediated marine yessotoxin delivery for cancer therapy

Author:

Vieira Ana MG12ORCID,Silvestre Oscar F1ORCID,Silva Bruno FB1ORCID,Ferreira Celso JO13ORCID,Lopes Ivo2,Gomes Andreia C24ORCID,Espiña Begoña1ORCID,Sárria Marisa P1ORCID

Affiliation:

1. International Iberian Nanotechnology Laboratory (INL), Avenida Mestre José Veiga, Braga, 4715-330, Portugal

2. Centre of Molecular & Environmental Biology (CBMA), University of Minho, Braga, 4710-057, Portugal

3. Centro de Física das Universidades do Minho e do Porto (CF-UM-UP), University of Minho, Braga, 4710-057, Portugal

4. Institute of Science & Innovation for Biosustainability (IB-S), University of Minho, Braga, 4710-057, Portugal

Abstract

Background: Yessotoxin (YTX), a marine-derived drug, was encapsulated in PEGylated pH-sensitive nanoliposomes, covalently functionalized (strategy I) with SDF-1α and by nonspecific adsorption (strategy II), to actively target chemokine receptor CXCR-4. Methods: Cytotoxicity to normal human epithelial cells (HK-2) and prostate (PC-3) and breast (MCF-7) adenocarcinoma models, with different expression levels of CXCR-4, were tested. Results: Strategy II exerted the highest cytotoxicity toward cancer cells while protecting normal epithelia. Acid pH-induced fusion of nanoliposomes seemed to serve as a primary route of entry into MCF-7 cells but PC-3 data support an endocytic pathway for their internalization. Conclusion: This work describes an innovative hallmark in the current marine drug clinical pipeline, as the developed nanoliposomes are promising candidates in the design of groundbreaking marine flora-derived anticancer nanoagents.

Funder

FP7 People: Marie-Curie Actions

Fundação para a Ciência e a Tecnologia

Fundo Regional for Ciência e Tecnologia da Região Autónoma dos Açores

NORTE2020

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Reference118 articles.

1. ECIS- European Cancer Information System. Estimates of cancer incidence and mortality in 2020, for all cancer sites (2020). https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-AE27$2-All$4-1,2$3-All$6-0,85$5-2020,2020$7-7$CEstByCancer$X0_8-3$CEstRelativeCanc$X1_8-3$X1_9-AE27$CEstBySexByCancer$X2_8-3$X2_-1-1

2. Cancer treatment and survivorship statistics, 2016

3. American Cancer Society. How chemotherapy drugs work (2016). www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.html

4. New Soft Alkylating Agents with Enhanced Cytotoxicity against Cancer Cells Resistant to Chemotherapeutics and Hypoxia

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3